Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei W. Wu, Zaixin Zhong, Fengze Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li, Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng, Jinghua Yan, Zhongyu Hu, Lidong Gao, George F. Gao
Topics & Concepts
ImmunogenicityRecombinant DNAPlaceboDouble blindVirologyMedicineCoronavirus disease 2019 (COVID-19)Protein subunitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInternal medicineBiologyAntibodyGeneticsPathologyGeneAlternative medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies